皮内狂犬病暴露后免疫:一周四剂次方案与更新泰国红十字会方案的非劣效随机试验
在菲律宾开展的单中心III期开放标签随机对照试验纳入600例≤50岁暴露于疑似狂犬病动物者,比较一周四剂次皮内方案(有或无狂犬病免疫球蛋白)与28天两剂次更新泰国红十字会方案。第14天血清阳转率非劣效,三组分别为100%、99.4%、98.8%,第1年降至97.6%、89%、79.8%。
要点
- 一周四剂次皮内方案第14天血清阳转率非劣效于28天两剂次方案。
- 第14天抗体几何平均滴度三组分别为11.3、9.89、6.15 IU/mL。
- 三组安全性和耐受性相似。
核心结论
- 一周四剂次皮内方案联合或不联合纯化马狂犬病免疫球蛋白,第14天血清阳转率均非劣效于28天两剂次更新泰国红十字会方案联合纯化马狂犬病免疫球蛋白。
研究设计与样本
- III期单中心开放标签随机对照试验,纳入600例≤50岁暴露于疑似狂犬病动物且为WHO II类或III类暴露者。
- G1(n=200)为一周六剂次皮内方案无狂犬病免疫球蛋白,G2(n=201)为同方案联合纯化马狂犬病免疫球蛋白,G3(n=199)为28天两剂次更新泰国红十字会方案联合纯化马狂犬病免疫球蛋白。
- 血清阳转定义为快速荧光灶抑制试验测得狂犬病毒中和抗体滴度≥0.5 IU/mL。
主要发现
- 第14天血清阳转率G1为100%、G2为99.4%、G3为98.8%,两项非劣效比较均成立。
- 第1年血清阳转率分别降至97.6%、89%、79.8%。
- 第14天狂犬病毒中和抗体几何平均滴度分别为11.3 IU/mL、9.89 IU/mL、6.15 IU/mL,第1年降至2.96 IU/mL、1.37 IU/mL、0.97 IU/mL。
- 三组安全性和耐受性相似。
临床怎么用
- 在暴露后预防中,可考虑采用一周四剂次皮内方案替代28天两剂次方案,联合或不联合纯化马狂犬病免疫球蛋白。
- 需关注第1年抗体持久性下降,尤其联合纯化马狂犬病免疫球蛋白组血清阳转率降至89%。
局限性
- 单中心开放标签设计可能引入偏倚。
- 仅纳入≤50岁且为WHO II类或III类暴露者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rabies post-exposure prophylaxis (PEP) via intradermal (ID) administration is standard practice in Asia. Accumulating evidence suggests that PEP shortened to 3 visits in one week does not adversely affect seroconversion rates or immune memory. OBJECTIVE: To determine whether the seroconversion rate at Day14 with a 1-week, 4-site (4-4-4-0-0) ID vaccination regimen with or without rabies immunoglobulin (RIG) was non-inferior to the updated Thai Red Cross (TRC) 28-day, 2-site (2-2-2-0-2) ID regimen with RIG during rabies PEP. We also assessed one-year antibody persistence. METHODS: This phase III, mono-center, open-label, randomized-controlled trial assigned participants aged ≤50 years (n = 600) exposed to suspected rabid animals and sustaining WHO Category II injuries (automatic allocation to G1) or Category III injuries (randomized to G2 or G3) to the following groups (1:1:1 ratio): G1 (n = 200), 1-week 4-site ID regimen with the purified Vero cell rabies vaccine (PVRV; Verorab®) without RIG; G2 (n = 201), 1-week 4-site ID regimen with PVRV, and purified equine rabies immunoglobulin (pERIG); G3 (n = 199), TRC 28-day, 2-site ID regimen with PVRV, and pERIG. Non-inferiority tests compared G1 vs. G3 and G2 vs. G3. Seroconversion rate was the proportion (%) of vaccinees with rabies virus neutralizing antibodies (RVNA) titers ≥0.5 IU/mL measured by rapid fluorescent focus inhibition test. RESULTS: On Day14, after the third vaccine administration, seroconversion rates were non-inferior in both comparisons and were, respectively, 100%, 99.4%, 98.8% in G1, G2, G3 with a decrease to 97.6%, 89%, 79.8% at Year 1. At Day14, RVNA geometric mean titers were 11.3 IU/mL; 9.89 IU/mL; 6.15 IU/mL, respectively, decreasing to 2.96 IU/mL, 1.37 IU/mL, 0.97 IU/mL at Year1. Safety and tolerability were similar between the three groups. CONCLUSION: The seroconversion rate at Day 14 with the 1-week 4-site ID regimen, both with and without pERIG, was non-inferior to the reference TRC 28-day 2-site ID regimen with pERIG during rabies PEP with PVRV. ClinicalTrials.gov ID: NCT01622062.
引用
- Quiambao BP, Ambas C, Diego S, et al. Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines. Vaccine. 2019. PMID: 30890382. doi:10.1016/j.vaccine.2019.02.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。